Linked Life Data

3283769

Source:http://linkedlifedata.com/resource/pubmed/id/3283769

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1988-6-7
pubmed:abstractText
Reported rates of tumour response for metastatic bladder cancer vary widely among different institutions, even when similar drug regimens are employed. These differences are due to selection of patients, quality of supportive care, and to methodological differences in the design, analysis and reporting of clinical trials. Because of these factors, intercomparison of response rates from different phase 2 trials is not very meaningful. Trials from the Princess Margaret Hospital have demonstrated palliation from several regimens, but it remains uncertain whether aggressive regimens using several drugs are superior to less toxic chemotherapy. Current clinical trials which randomize patients to receive aggressive chemotherapy or single agents should help to resolve some of these problems.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0361-7742
pubmed:author
pubmed:issnType
Print
pubmed:volume
260
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
487-98
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Analysis of trials using chemotherapy for metastatic bladder cancer.
pubmed:affiliation
Department of Medicine, Princess Margaret Hospital, Ontario, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Review